Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis and Disease Progression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-15

Study Completion Date

2029-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

\[68Ga\]Ga-PentixaFor PET-CT will be performed in patients with Small cell lung cancer (SCLC) to confirm the targeting of CXCR4 by \[68Ga\]Ga-PentixaFor

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

NCT03792074

Non-squamous Cell Non-small Cell Lung Cancer

UNKNOWN PHASE3

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

NCT05570825

Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage IIIC Lung Cancer AJCC v8 +1 more

RECRUITING PHASE2

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

NCT06375109

Limited-stage Small-cell Lung Cancer

NOT_YET_RECRUITING PHASE2

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

NCT04297605

Non-small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE1

Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma

NCT04312204

Primary Pulmonary Lymphoepithelioma-like Carcinoma Lung Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers, but remains a cancer with a poor prognosis, often detected at a metastatic stage and associated with a high rate of early recurrence.

Therapeutic options for unresectable SCLC are limited and essentially rely on first-line radiochemotherapy for limited disease or chemo-immunotherapy, possibly supplemented by radiotherapy, for extensive disease.

CXCR4 is a chemokine receptor that is highly expressed in this cancer. By targeting CXCR4 with \[177Lu\]Lu-PentixaTher or \[90Y\]Y-PentixaTher, patients with SCLC could benefit from a new type of treatment in this indication: Peptide Receptor Radionuclide Therapy (PRRT).

However, there is a need for a preliminary diagnostic study due to a lack of published data.

\[68Ga\]Ga-PentixaFor is an experimental compound that binds with high affinity to CXCR4 and appears to be a promising candidate for PET-CT imaging of SCLC. This initial step is crucial to confirm CXCR4 targeting by \[68Ga\]Ga-PentixaFor before considering PRRT with therapeutic radionuclides such as Lu-177 or Y-90 in future trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Cell Lung Carcinoma (SCLC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[68Ga]Ga-PentixaFor

The patient receives a single dose I.V. injection of \[68Ga\]Ga-PentixaFor 150 (± 50) MBq, corresponding to a peptide mass dose of ≤ 50 μg per administration.

Group Type EXPERIMENTAL

[68Ga]Ga-PentixaFor

Intervention Type DRUG

\[68Ga\]Ga-PentixaFor PET-CT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[68Ga]Ga-PentixaFor

\[68Ga\]Ga-PentixaFor PET-CT

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent signed before performing any trial specific procedure.
2. Male or female, age ≥ 18 years at time of study entry.
3. Patient with histologically proven small cell lung carcinoma, inoperable, non-pre-treated.
4. Metastatic disease documented by conventional imaging and/or \[18F\]FDG PET-CT with at least one metastatic measurable lesion (RECIST 1.1). Patients eligible for 1st line metastatic treatment.
5. Availability of tissue material (primary lesion and/or metastatic site) to allow additional immunohistochemical studies.
6. PS \< 2.
7. Consent to use a contraception method for at least 3 months after each administration of \[68Ga\]Ga-PentixaFor.
8. Adequate Organ function confirmed by laboratory test results allowing for safe the \[68Ga\]Ga-PentixaFor administration.
9. Life expectancy greater than 3 months.
10. Patient has valid health insurance.
11. Patient willing and able to comply with the protocol throughout the duration of the study, including during treatment and scheduled visits and examinations, including follow-up.

Exclusion Criteria

1. History of cancer in the 3 years prior to entry into the trial other than basal cell carcinoma of the skin or carcinoma in situ of the cervix.
2. History of anti-cancer treatments such as chemotherapy, radiotherapy or immunotherapy as well as other clinical trials for SCLC before the first \[68Ga\]Ga-PentixaFor PET-CT imaging.
3. Inability to lie still for at least 1 hour, or known claustrophobia.
4. Serious non-malignant disease (e.g., psychiatric, infectious, autoimmune, or metabolic) which may interfere with study objectives or patient safety or compliance, in the judgment of the investigator.
5. Unstable diabetes with blood glucose \> 2 g/L.
6. Known hypersensitivity to any active pharmaceutical agent or constituent of the \[68Ga\]Ga-PentixaFor and/or \[18F\]FDG product.
7. Body weight of less than 48 kg.
8. Mental impairment that may compromise the ability to give informed consent and comply with study requirements.
9. Pregnant, likely to be pregnant or breastfeeding woman.
10. Patient deprived of liberty, under judicial safeguard, under curatorship or placed under the authority of a guardian.
11. Disorder preventing understanding of trial information or informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No